Last 7 days
-5.7%
Last 30 days
1.2%
Last 90 days
-4.6%
Trailing 12 Months
-25.4%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 310.3B | 1.6B | -8.12% | 92.29% | -161.87 | 199.29 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -13.97% | -3.48% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -7.48% | 7.49% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 85.7B | 9.2B | 0.30% | 24.35% | 26.28 | 9.3 | 15.86% | 32.99% |
ALNY | 23.1B | 1.0B | -9.21% | 46.34% | -21.7 | 22.28 | 22.88% | -19.27% |
SRPT | 12.0B | 975.7M | 3.69% | 90.82% | -10.76 | 12.3 | 27.41% | -212.78% |
UTHR | 9.9B | 2.0B | -6.22% | -2.22% | 13.62 | 5 | 12.05% | 52.86% |
MID-CAP | ||||||||
MDGL | 5.1B | 504.0K | -4.45% | 362.54% | -16.36 | 2.5K | -66.53% | -27.52% |
RARE | 3.5B | 363.3M | 14.61% | 9.13% | -4.95 | 9.64 | 3.39% | -55.81% |
BPMC | 3.3B | 204.6M | 20.71% | 4.83% | -5.64 | 16.03 | -7.52% | 10.65% |
MRTX | 2.2B | 18.9M | 1.15% | -25.44% | -3.03 | 118.18 | - | -16.17% |
SMALL-CAP | ||||||||
CYTK | 3.6B | - | -0.47% | -0.26% | -8.26 | 37.64 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -28.87% | 71.03% | 12.35 | 4.79 | 66.85% | 120.61% |
MGNX | 318.5M | 165.3M | -20.15% | 43.43% | -3.49 | 1.93 | 130.70% | 57.97% |
CRBP | 43.9M | 881.7K | 8.16% | 3439.25% | -0.87 | 19.11 | -77.61% | -29.84% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 51.9% | 18,894,000 | 12,436,000 | |||
Operating Expenses | 2.1% | 788,088,000 | 772,025,000 | 756,742,000 | 716,160,000 | 697,779,000 |
S&GA Expenses | 8.1% | 259,337,000 | 239,798,000 | 212,512,000 | 186,897,000 | 162,280,000 |
R&D Expenses | -0.8% | 527,334,000 | 531,627,000 | 544,230,000 | 529,263,000 | 535,499,000 |
EBITDA | 0.8% | -737,430,000 | -743,254,000 | -576,350,000 | - | - |
EBITDA Margin | - | -59.30 | - | - | - | - |
Earnings Before Taxes | 0.7% | -740,359,000 | -745,854,000 | - | - | - |
EBT Margin | - | -59.53 | - | - | - | - |
Net Income | 0.5% | -737,067,000 | -740,867,000 | -738,012,000 | -644,505,000 | -634,490,000 |
Net Income Margin | - | -59.57 | - | - | - | - |
Free Cahsflow | 1.9% | -575,421,000 | -586,445,000 | -496,437,000 | -448,681,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -14.0% | 1,034 | 1,203 | 1,303 | 1,280 | 1,421 |
Current Assets | -15.3% | 939 | 1,109 | 1,226 | 1,203 | 1,343 |
Cash Equivalents | 3.1% | 243 | 235 | 299 | 266 | 305 |
Inventory | 27.5% | 4.00 | 3.00 | - | - | - |
Net PPE | -2.0% | 17.00 | 18.00 | 18.00 | 17.00 | 17.00 |
Liabilities | -17.0% | 171 | 206 | 174 | 168 | 172 |
Current Liabilities | -21.9% | 125 | 159 | 127 | 119 | 124 |
Shareholder's Equity | -13.4% | 863 | 997 | 1,129 | 1,112 | 1,249 |
Retained Earnings | -7.5% | -2,637 | -2,452 | -2,250 | -2,076 | -1,900 |
Additional Paid-In Capital | 1.4% | 3,502 | 3,453 | 3,386 | 3,185 | 3,145 |
Shares Outstanding | 0.5% | 58.00 | 58.00 | 58.00 | 56.00 | 56.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -5.2% | -600,283 | -570,570 | -579,755 | -488,978 | -438,853 |
Share Based Compensation | 2.2% | 190,244 | 186,188 | 158,459 | 142,400 | 131,685 |
Cashflow From Investing | 64.5% | 371,399 | 225,803 | -4,332 | -17,573 | -83,818 |
Cashflow From Financing | -0.5% | 166,144 | 166,944 | 640,306 | 491,433 | 497,864 |
99.2%
88.1%
68.5%
Y-axis is the maximum loss one would have experienced if Mirati Therapeutics was unfortunately bought at previous high price.
75.6%
13.7%
-0.2%
-24.4%
FIve years rolling returns for Mirati Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-22 | AMERIPRISE FINANCIAL INC | sold off | -100 | -28,869,000 | - | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | added | 0.36 | -1,850,000 | 8,634,000 | 0.01% |
2023-05-18 | INTERNATIONAL BIOTECHNOLOGY TRUST PLC | unchanged | - | -1,983,720 | 9,071,920 | 2.53% |
2023-05-18 | JPMORGAN CHASE & CO | added | 39.16 | 276,000 | 2,225,000 | -% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -46.3 | -3,379,000 | 2,662,000 | 0.01% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | sold off | -100 | -474,912 | - | -% |
2023-05-16 | JANE STREET GROUP, LLC | reduced | -21.6 | -3,074,290 | 5,544,580 | -% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 435 | 10,414,800 | 13,481,900 | -% |
2023-05-16 | Utah Retirement Systems | sold off | -100 | -348,887 | - | -% |
2023-05-16 | Castleview Partners, LLC | sold off | -100 | -226 | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | armistice capital, llc | 6.06% | 3,488,000 | SC 13G | |
Feb 14, 2023 | avoro capital advisors llc | 9.6% | 5,555,555 | SC 13G/A | |
Feb 14, 2023 | rtw investments, lp | 6.3% | 3,643,114 | SC 13G | |
Feb 14, 2023 | perceptive advisors llc | 3.8% | 2,191,425 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.64% | 4,973,888 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 5.24% | 3,016,335 | SC 13G/A | |
Feb 15, 2022 | perceptive advisors llc | 5.9% | 3,283,783 | SC 13G/A | |
Feb 11, 2022 | avoro capital advisors llc | 9.2% | 5,075,000 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 5.70% | 3,145,632 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
May 24, 2023 | 8-K | Current Report | |
May 24, 2023 | 4 | Insider Trading | |
May 12, 2023 | S-8 | Employee Benefits Plan | |
May 12, 2023 | 8-K | Current Report | |
May 09, 2023 | 8-K | Current Report | |
May 09, 2023 | 10-Q | Quarterly Report | |
Apr 06, 2023 | DEF 14A | DEF 14A | |
Apr 05, 2023 | ARS | ARS | |
Feb 28, 2023 | 8-K | Current Report | |
Feb 28, 2023 | 10-K | Annual Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-24 | Christensen Jamie | sold | -28,034 | 45.2905 | -619 | evp & chief scientific officer |
2023-01-20 | FUCHS HENRY J | acquired | - | - | 4,444 | - |
2023-01-20 | Johnson Craig A | acquired | - | - | 4,444 | - |
2023-01-20 | Meek David D. | acquired | - | - | 89,379 | chief executive officer |
2023-01-20 | Christensen Jamie | acquired | - | - | 26,864 | evp, chief scientific officer |
2023-01-20 | Cherrington Julie M | acquired | - | - | 4,444 | - |
2023-01-20 | Stelzer Laurie | acquired | - | - | 26,864 | cfo |
2023-01-20 | Sharp Shalini | acquired | - | - | 4,444 | - |
2023-01-20 | Hickey Benjamin | acquired | - | - | 36,394 | evp, chief commercial officer |
2023-01-20 | Hasnain Faheem | acquired | - | - | 6,333 | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Total revenue | $ 7,167 | $ 709 |
Revenue | ||
Total revenue | 7,167 | 709 |
Operating expenses | ||
Cost of product revenue | 558 | 0 |
Cost of product revenue - intangible asset amortization | 259 | 0 |
Research and development | 126,683 | 130,976 |
Selling, general and administrative | 73,490 | 53,951 |
Total operating expenses | 200,990 | 184,927 |
Loss from operations | (193,823) | (184,218) |
Other income (expense), net | 9,237 | (4,168) |
Net loss | (184,586) | (188,386) |
Foreign currency translation adjustment | (31) | 0 |
Unrealized gain (loss) on available-for-sale investments | 2,043 | (4,802) |
Comprehensive loss | $ (182,574) | $ (193,188) |
Basic net loss per share (USD per share) | $ (3.18) | $ (3.40) |
Diluted net loss per share (USD per share) | $ (3.18) | $ (3.40) |
Weighted average common shares outstanding, basic (shares) | 58,031,642 | 55,468,851 |
Weighted average common shares outstanding, diluted (shares) | 58,031,642 | 55,468,851 |
Product Revenue | ||
Total revenue | $ 6,291 | $ 0 |
Revenue | ||
Total revenue | 6,291 | 0 |
License and Collaboration Revenue | ||
Total revenue | 876 | 709 |
Revenue | ||
Total revenue | $ 876 | $ 709 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 241,925 | $ 235,260 |
Short-term investments | 660,369 | 848,577 |
Accounts receivable, net | 6,227 | 865 |
Inventory | 3,849 | 3,020 |
Other current assets | 26,980 | 21,239 |
Total current assets | 939,350 | 1,108,961 |
Property and equipment, net | 17,185 | 17,540 |
Intangible asset, net | 14,655 | 14,914 |
Long-term investment | 3,353 | 3,465 |
Right-of-use asset | 35,783 | 36,122 |
Other long-term assets | 23,435 | 21,645 |
Total assets | 1,033,761 | 1,202,647 |
Current liabilities | ||
Accounts payable | 22,320 | 38,861 |
Accrued liabilities | 102,280 | 120,587 |
Total current liabilities | 124,600 | 159,448 |
Lease liability | 43,227 | 43,661 |
Other liabilities | 3,304 | 3,022 |
Total liabilities | 171,131 | 206,131 |
Commitments and contingencies (see Note 11) | ||
Shareholders' equity | ||
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both March 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 authorized; 58,148,416 and 57,854,559 issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 58 | 58 |
Additional paid-in capital | 3,501,754 | 3,453,066 |
Accumulated other comprehensive loss | (1,707) | (3,719) |
Accumulated deficit | (2,637,475) | (2,452,889) |
Total shareholders' equity | 862,630 | 996,516 |
Total liabilities and shareholders' equity | $ 1,033,761 | $ 1,202,647 |